Chapter XII-DA - SPECIAL PROVISIONS RELATING TO TAX ON DISTRIBUTED INCOME OF DOMESTIC COMPANY FOR BUY-BACK OF SHARES (From Section 115QA to Section 115QC)
Part C - Procedure for filing of return in respect of fringe benefits, assessment and payment of tax in respect thereof (From Section 115WD to Section 115WM)
Chapter XX-B - REQUIREMENT AS TO MODE OF ACCEPTANCE, PAYMENT OR REPAYMENT IN CERTAIN CASES TO COUNTERACT EVASION OF TAX (From Section 269SS to Section 269TT)
Research expenditure deductions: enhanced tax relief available for approved payments and in house R&D, subject to approval and compliance. Section 35 allows deductions for revenue and capital expenditure on scientific research related to business, permits enhanced deductions for payments to approved research associations, universities, specified institutions, National Laboratories and certain companies, and for in house R&D facilities of qualifying businesses, subject to prescribed approvals, notifications, reporting, and procedural compliance; it prevents double claims, prescribes amortisation and cessation/sale treatment for capital research assets, and imposes approval and certification conditions on recipients as prerequisite to donor deductions.
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Research expenditure deductions: enhanced tax relief available for approved payments and in house R&D, subject to approval and compliance.
Section 35 allows deductions for revenue and capital expenditure on scientific research related to business, permits enhanced deductions for payments to approved research associations, universities, specified institutions, National Laboratories and certain companies, and for in house R&D facilities of qualifying businesses, subject to prescribed approvals, notifications, reporting, and procedural compliance; it prevents double claims, prescribes amortisation and cessation/sale treatment for capital research assets, and imposes approval and certification conditions on recipients as prerequisite to donor deductions.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.